Larimar Therapeutics Inc.

Biotechnology, Biotechnology & rare disease, Biotechnology, Biotechnology: pharmaceutical preparations, Health care
Founded in 2016
Bala Cynwyd, Pennsylvania
http://www.larimartx.com
None

About Larimar Therapeutics Inc.

Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 52.4M None
  • Last Funding: 3.4M None (None)
  • Funding Status: None

Technology Stack

Larimar Therapeutics Inc. actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Biotechnology & rare disease, Biotechnology, Biotechnology: pharmaceutical preparations, Health care

Headquarters: Bala Cynwyd, Pennsylvania